eIF4E3 Activators
eIF4E3 Activators represent a specialized class of chemical compounds that are designed to specifically enhance the activity of the eukaryotic translation initiation factor 4E type 3 (eIF4E3), a protein involved in the initiation phase of mRNA translation. These activators are crucial because eIF4E3 plays a pivotal role in the selective translation of mRNAs that are essential for cellular growth and differentiation. The compounds that act as eIF4E3 Activators typically function by binding to eIF4E3 and facilitating its interaction with the mRNA cap structure or by enhancing its association with other protein partners within the eIF4F complex. By doing so, they amplify the protein's inherent ability to initiate translation, leading to an upsurge in protein synthesis within the cell. Some activators might achieve this by stabilizing eIF4E3 or by preventing its sequestration by inhibitory proteins, thus ensuring that it remains available for initiating translation.
The molecular mechanisms by which eIF4E3 Activators exert their effects are diverse, yet they share the common goal of promoting the assembly of the translation initiation complex. For instance, some activators may mimic the cap structure of mRNA, thus binding to eIF4E3 and enhancing its affinity for the actual mRNA cap. Others might influence the phosphorylation state of eIF4E3, which is a critical determinant of its activity; phosphorylated eIF4E3 has a higher affinity for the cap structure, and thus activators that promote its phosphorylation effectively increase the translation initiation rate. The precise modulation of eIF4E3 activity by these activators is a testament to the intricate regulation of protein synthesis, which is a fundamental cellular process. These activators operate by fine-tuning the interactions within the eIF4F complex and the broader regulatory networks that govern mRNA translation, ensuring that the right proteins are synthesized at the right time, thus maintaining cellular homeostasis and responding to the cell's metabolic demands.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can indirectly enhance eIF4E3 activity by reducing the inhibitory phosphorylation of 4E-BPs, which are proteins that sequester eIF4E3, thus freeing eIF4E3 to initiate translation. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
This selective mTOR kinase inhibitor can enhance eIF4E3 activity by a similar mechanism to rapamycin, providing more specificity and potentially fewer off-target effects. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
A dual PI3K/mTOR inhibitor that can upregulate eIF4E3 activity by alleviating feedback inhibition on the mTOR pathway, which in turn can decrease 4E-BP-mediated suppression of eIF4E3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can indirectly augment eIF4E3 activity by inhibiting the PI3K/Akt/mTOR pathway, reducing the inhibitory effects of 4E-BP on eIF4E3. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that might enhance eIF4E3 activity through cell cycle arrest, leading to reduced phosphorylation of translational control proteins, including 4E-BPs. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
A sirtuin activator that can enhance eIF4E3 activity indirectly by activating AMPK, which can modulate the mTOR pathway and decrease the suppressive effects of 4E-BPs on eIF4E3. | ||||||
1,1-Dimethylbiguanide, Hydrochloride | 1115-70-4 | sc-202000F sc-202000A sc-202000B sc-202000C sc-202000D sc-202000E sc-202000 | 10 mg 5 g 10 g 50 g 100 g 250 g 1 g | $20.00 $43.00 $63.00 $156.00 $260.00 $510.00 $31.00 | 37 | |
An AMPK activator that can enhance eIF4E3 activity by modulating the mTOR pathway and reducing the suppressive interaction between eIF4E3 and 4E-BPs. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
This AMPK agonist enhances eIF4E3 activity by activating AMPK, leading to inhibited mTOR signaling and reduced 4E-BP-mediated suppression of eIF4E3. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
An mTOR inhibitor that can enhance eIF4E3 activity by relieving 4E-BP-mediated sequestration of eIF4E3, thus promoting its participation in translational initiation. | ||||||
SBI-0206965 | 1884220-36-3 | sc-507431 | 10 mg | $124.00 | ||
An ULK1 inhibitor that can indirectly enhance eIF4E3 activity by modulating autophagy pathways, which can influence the mTOR pathway and 4E-BP interaction with eIF4E3. | ||||||